GlassScriptPhysician profile
Kayleigh King
NPI 1821219114
$7,204.29
in general payments reported to CMS, 2019-2025
52 companies · $2,737 in 2025
The $2,737 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $451 · 2023: $247 · 2024: $3,024 · 2025: $2,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.03 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $576.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,401.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $522.60 | 2024-2025 | Enhertu, Lynparza, Calquence |
| Abbvie INC. | $468.80 | 2021-2025 | |
| Lilly USA, LLC | $364.44 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $316.92 | 2024-2025 | Enhertu |
| Abbott Laboratories | $262.99 | 2023-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $245.35 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $245.31 | 2024-2025 | Rybrevant, Tecvayli, Erleada |
| Incyte Corporation | $225.87 | 2024-2025 | Jakafi, Zynyz |
| Merck Sharp & Dohme LLC | $221.74 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $217.87 | 2021-2025 | Vyloy, Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $201.85 | 2024-2025 | Opdivo |
| Spectrum Pharmaceuticals INC. | $187.14 | 2024 | Rolvedon |
| Novo Nordisk INC | $182.05 | 2021-2022 | |
| Eisai INC. | $178.82 | 2024-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayleigh King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.